



## Drug Formulary Update, January 2021 Medicare

Updates to the HealthPartners Medicare 2021 Formulary are listed below.

Please see [www.healthpartners.com/formularies](http://www.healthpartners.com/formularies) for details.

Updates are effective January 1, 2021.

Drug name	Current Status	New Status	Comments
Bafiertam	NF	T5, QL	A new FDA-approval
Bynfezia	NF	T5, PA	A new FDA-approval
Dojolvi	NF	T5, PA	A new FDA-approval
Dulera	T4, PA	T4, PA	PA criteria update
Enspryng	NF	T5, PA	A new FDA approval
Epclusa 200mg-50mg	NF	T5, PA	A new FDA-approval
Eucrisa 2% ointment	T4, PA, QL	T4, PA, QL	PA criteria update
Evrysdi	NF	T5, PA	A new FDA-approval
Isturisa	NF	T5, PA	A new FDA-approval
Kesimpta	NF	T5, QL	A new FDA-approval
Oriahnn	NF	T5, PA, QL	A new FDA-approval
Xywav	NF	T5, PA, QL	A new FDA-approval
Zeposia	NF	T5, QL	A new FDA-approval

T1 =Preferred Generic, T2 = Generic, T3 = Preferred Brand, T4 = Non-Preferred Drug,  
T5 = Specialty, NF = Non-Formulary, PA = Prior Authorization, QL = Quantity Limit